Blow for Eli Lilly as research institute deems diabetes candidate no better than competition

Eli Lilly’s tirzepatide – presumably the biggest competition for Novo Nordisk’s new generation of diabetes drugs – is not more effective than other type 2 diabetes treatments on the market.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app